YOLFTbeta
Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE · NASDAQ · Healthcare / Biotechnology

1.81USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.81
Open1.82
Day Range1.81 – 1.83
52-Week Range1.79 – 5.18
Volume13.56K
Market Cap45.44M
P/E (TTM)0.00
Forward P/E2.17
EPS-1.19
Dividend Yield0.00%
Beta0.44
50-Day Avg2.18
200-Day Avg3.01

About

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Prashant Kohli
  • Employees5
  • Headquarters103 Carnegie Center, Princeton, NJ, United States, 08540, USA
  • Websitehttps://www.gracetx.com

Leadership

  • Mr. Prashant KohliCEO & Director · b. 1972
  • Mr. Amresh Kumar Ph.D.VP of Program Management · b. 1980
  • Ms. Carrie D'AndreaConsultant · b. 1973
  • Mr. Robert J. DelAversano CPAVP of Finance and Principal Financial & Accounting Officer · b. 1972
  • Dr. R. Loch MacDonald M.D., Ph.D.Member of Scientific Advisory Board & Chief Medical Officer · b. 1962

Financials

Income Statement

Currency: USD2009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue--27.33K10.47K707.39K450.16K300.50K39.20K----309.32K00000
Growth (%)----61.67%+6653.17%-36.36%-33.25%-86.96%------100.00%----
Cost of Revenue3.55K8.58K12.55K5.11K396.94K262.30K2.85M2.58M2.57M2.68M3.12M-119.94K0124.00K11.00K7.00K7.00K
Gross Profit-3.55K-8.58K29.04K5.37K310.45K187.86K-2.55M-2.54M-2.57M-2.68M-3.12M-189.38K0-124.00K-11.00K-7.00K-7.00K
Gross Margin--106.25%51.25%43.89%41.73%-849.81%-6475.12%----61.22%-----
Operating Expense1.19M1.53M3.11M6.56M7.13M9.89M7.35M7.29M7.95M12.57M31.28M-26.10M19.48M70.42M17.43M23.75M11.07M
Operating Income-1.20M-1.54M-3.08M-6.55M-6.82M-9.71M-9.91M-9.83M-10.52M-15.25M-34.41M-48.83M-25.91M-19.48M-70.54M-17.44M-23.75M-11.08M
Operating Margin---11283.59%-62535.93%-963.79%-2156.17%-3296.73%-25072.30%-----8377.05%-----
EBITDA-1.16M-1.53M-2.39M-5.86M-6.08M-8.84M-8.04M-2.89M-7.95M-14.30M-36.76M-45.85M-15.45M-19.17M-24.51M-15.37M-23.74M-11.07M
EBITDA Margin---8741.72%-55922.51%-859.53%-1963.93%-2675.68%-7383.80%-----4995.93%-----
Net Income-1.17M-1.51M-3.08M-6.54M-6.73M-10.44M-1.32M-4.66M-10.56M-16.65M-39.37M-50.98M-31.05M-12.27M-57.39M-17.44M-13.63M-7.79M
Net Income Margin---11254.24%-62421.58%-951.73%-2318.28%-440.18%-11892.78%-----10039.81%-----
R&D641.28K1.12M1.57M3.12M2.94M5.45M7.05M5.58M7.18M12.13M29.37M31.92M6.59M6.95M13.49M6.35M13.54M2.40M
R&D as % of Total Revenue--5754.52%29811.74%415.50%1209.75%2346.41%14244.23%----2129.08%-----
Interest Expense-431.931.43K9.01K2.62K876.283.24K1.48K54.44K371.62K1.05M414.18K331.65K-----
Interest Expense % of Total Revenue--5.24%86.05%0.37%0.19%1.08%3.77%----107.22%-----

Balance Sheet

Currency: USD2009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets2.63M8.90M11.07M15.82M11.89M41.01M29.74M21.04M25.48M17.78M36.90M32.30M78.46M128.62M79.12M73.30M71.99M66.65M
Total Liabilities12.58M4.88M5.24M1.27M2.39M11.10M3.18M957.12K3.76M11.41M25.85M13.94M8.54M20.35M11.17M11.56M5.38M2.76M
Total Equity-9.95M4.02M5.83M14.55M9.50M29.91M26.56M20.09M21.72M6.37M11.04M18.37M69.92M108.27M67.95M61.74M66.61M63.90M
Cash327.64K404.96K329.43K1.60M1.17M607.09K1.05M2.23M-6.37M16.87M20.13M64.00M30.34M27.88M23.00M22.13M16.98M
Total Debt--------1.41M1.25M1.36M207.79K108.04K295.00K485.00K---
Net Debt-327.64K-404.96K-329.43K-1.60M-1.17M-607.09K-1.05M-2.23M1.41M-5.12M-15.51M-19.92M-63.89M-30.04M-27.39M-23.00M-22.13M-16.98M

Cash Flow

Currency: USD2009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-157.52K-1.90M-1.91M-5.65M-2.49M-6.12M-5.75M-4.85M-6.94M-9.69M-24.79M-32.44M-17.99M-17.23M-15.91M-12.33M-14.90M-8.87M
Investing Cash Flow-2.34M1.90M-2.57M-3.01M1.85M-17.48M6.10M6.07M6.85M-318.26K-9.44M11.50M-12.38M-3.52M13.15M104.00K--
Financing Cash Flow2.88M77.40K4.40M9.94M221.53K22.44M36.77K-2.21K7.00M8.83M45.69M18.64M74.73M0304.00K7.36M14.03M3.71M
Capital Expenditure28.86K15.36K21.57K0100.68K133.56K68.73K271.56K2.57M352.33K534.00K450.93K86.68K017.00K22.00K00
Free Cash Flow-186.38K-1.92M-1.94M-5.65M-2.59M-6.25M-5.82M-5.12M-9.51M-10.05M-25.32M-32.89M-18.07M-17.23M-15.93M-12.36M-14.90M-8.87M
FCF to OCF118.33%100.81%101.13%100.00%104.04%102.18%101.19%105.60%137.02%103.63%102.15%101.39%100.48%100.00%100.11%100.18%100.00%100.00%

Earnings

Report DateMay 31, 2011Aug 31, 2011Nov 30, 2011Feb 29, 2012May 31, 2012Aug 31, 2012Nov 30, 2012May 28, 2013Jul 31, 2013Oct 30, 2013Jan 14, 2014May 22, 2014Jul 15, 2014Oct 14, 2014Jan 13, 2015May 27, 2015Jul 14, 2015Oct 15, 2015Jan 13, 2016May 26, 2016Jul 12, 2016Oct 12, 2016Jan 13, 2017Aug 15, 2017Nov 14, 2017Feb 14, 2018Jun 27, 2018Aug 14, 2018Nov 14, 2018Feb 14, 2019Jun 26, 2019Aug 14, 2019Nov 13, 2019Feb 14, 2020Jun 29, 2020Aug 13, 2020Nov 16, 2020Feb 9, 2021Jun 22, 2021Aug 13, 2021Nov 10, 2021Feb 14, 2022Jun 21, 2022Aug 11, 2022Nov 14, 2022Feb 14, 2023Jun 23, 2023Aug 11, 2023Nov 13, 2023Feb 12, 2024Jun 21, 2024Aug 9, 2024Nov 13, 2024Feb 17, 2025Jun 23, 2025Aug 12, 2025Nov 13, 2025Feb 12, 2026Jun 18, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-------------14.40-14.40-14.40-----------13.44--12.96-6.72-4.80-0.11-8.09-5.28-4.59-0.09-3.89-3.17-2.50-0.04---0.62-1.00---1.01-0.14-0.37-0.35-0.31-0.47-0.36-0.50-0.46-0.40-0.31-0.34-0.39-0.20-0.18-
EPS Actual-8.02-13.20-14.97-10.91-10.42-11.44-10.76-12.86-12.63-19.46-21.19-10.654.80-14.4014.40-8.68-3.52-4.37-7.47-6.22-10.87-8.05-8.10-6.74-11.71-19.20-12.14-11.04-29.76-3.36-0.02-7.20-16.32-8.640.22-3.17-3.77-1.83-0.24-0.08-0.03-0.69-0.31-0.10-0.11-0.72-0.65-0.48-0.31-0.28-0.36-0.33-0.42-0.510.05-0.29-0.08-0.19-0.08-0.91-
Surprise------------133.33%0.00%200.00%-----------42.86%-14.81%-342.86%30.00%79.27%11.00%-209.09%-88.24%344.44%18.51%-18.93%26.80%-500.00%---11.29%69.00%--28.71%-364.29%-29.73%11.43%9.68%24.13%8.33%16.79%-11.67%112.55%6.45%76.47%51.28%60.00%-405.56%-
Timing------------After-hoursAfter-hoursAfter-hours----------Pre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market---Pre-marketPre-market--Pre-market-Pre-marketPre-marketPre-market-Pre-marketPre-market--Pre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap45.44M
Enterprise Value31.05M
Trailing P/E0.00
Forward P/E2.17
Price / Sales197.75
Price / Book0.93
EPS-1.19
Book Value2.96
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-10.36M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-36.19%
Return on Assets-10.81%
Shares Outstanding21.04M
Shares Float15.48M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 5.90
  • Strong Buy
    2

Ownership Breakdown

Institutions
31.51%
Insiders
18.68%
Retail / Other
49.81%

Top Institutional Holders

  • HPM Partners LLC
    849.05K4.04%
  • Eversept Partners, LP
    772.90K3.67%
  • Nantahala Capital Management, LLC
    728.20K3.46%
  • Bank of America Corp
    494.72K2.35%
  • Vanguard Capital Management, LLC
    401.66K1.91%
  • Citadel Advisors Llc
    349.74K1.66%
  • Renaissance Technologies Corp
    243.91K1.16%
  • Jane Street Group LLC
    167.10K0.79%
  • Two Sigma Investments LLC
    96.89K0.46%
  • Marshall Wace Asset Management Ltd
    91.42K0.43%
  • XTX Topco Ltd
    63.09K0.30%
  • Birchview Capital, LP
    50.00K0.24%
  • Diametric Capital, LP
    39.80K0.19%
  • UBS Group AG
    26.30K0.13%
  • KESTRA PRIVATE WEALTH SERVICES, LLC
    23.00K0.11%
  • Fundamentun, LLC
    11.16K0.05%
  • Springbok Capital Management, LLC
    10.07K0.05%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    400.35K1.90%
  • iShares Micro-Cap ETF
    34.95K0.17%
  • Vanguard Balanced Index Inv
    11.36K0.05%

Stock Splits

  • Jul 10, 20231:6
  • Aug 31, 20211:8
  • Oct 15, 20151:10